Pfizer joins the TriNetX network to ‘harness’ real world data

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/littlehenrabi)
(Image: Getty/littlehenrabi)
Pfizer will recruit patients with rare diseases and identify clinical trial sites with support from the TriNetX global health research network, which is becoming "the defacto platform" for research, says CEO.

As a network member, Pfizer gains access to data from various global healthcare organizations. The platform provides users with de-identified patient data integrated from EMRs, tumor registries, unstructured pathology reports, and molecular genomics data to support clinical study and protocol design, as well as site identification and patient recruitment.

“TriNetX is becoming the defacto platform for clinical research,”​ said Gadi Lachman, CEO of TriNetX.

The company’s global health research network includes more than 70 healthcare organizations globally. Currently, TriNetX is working with more than 25 of the top pharmaceutical companies, Lachman examined.

Dr. Mohanish Anand, head of study optimization at Pfizer said the company joined TriNetX “to harness real world data for clinical trial optimization, with the goal of accelerating our ability to bring new therapies to market.”

“Pfizer will use the real-time access to clinical, genomic and oncology data to design clinical trial protocols with greater efficiency. For example, we hope to reduce avoidable amendments by identifying and correcting overly restrictive inclusion and exclusion criteria early in the design process,”​ Anand explained in a press release.

TriNetX recently announced a new algorithm designed to further support clinical trial patient identification. The chemotherapy lines of treatment identification algorithm is able to understand treatment patterns, according to the company, which announced the new offering at the SCOPE Summit in February.

“We remain focused on developing new features and functionality to drive clinical trial optimization,”​ Lachman added.

Related news

Show more

Related products

show more

Local Lab Data Management

Local Lab Data Management

Q2 Solutions | 01-Jul-2020 | Technical / White Paper

When a clinical trial requires local or point-of-care laboratory testing, managing the resulting data can be a significant burden to both the sponsor and...

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Related suppliers

Follow us

Products

View more

Webinars